{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:22:59Z","timestamp":1760908979252},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T00:00:00Z","timestamp":1443225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00277-015-2486-9","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T06:29:00Z","timestamp":1443248940000},"page":"1981-1989","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)"],"prefix":"10.1007","volume":"94","author":[{"given":"Theo","family":"de Witte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Suciu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liv","family":"Meert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantijn","family":"Halkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Selleslag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roel","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Muus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,26]]},"reference":[{"issue":"25","key":"2486_CR1","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1182\/blood-2008-09-038935","volume":"113","author":"RM Stone","year":"2009","unstructured":"Stone RM (2009) How I, treat patients with myelodysplastic syndromes. Blood 113(25):6296\u20136303","journal-title":"Blood"},{"issue":"1","key":"2486_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00277-014-2177-y","volume":"94","author":"M Oosterveld","year":"2015","unstructured":"Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A et al (2015) Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. Ann Hematol 94(1):23\u201334","journal-title":"Ann Hematol"},{"issue":"17","key":"2486_CR3","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C et al (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122(17):2943\u20132964","journal-title":"Blood"},{"issue":"4","key":"2486_CR4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2141.1991.tb08616.x","volume":"77","author":"P Fenaux","year":"1991","unstructured":"Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77(4):497\u2013501","journal-title":"Br J Haematol"},{"issue":"9","key":"2486_CR5","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2403035","volume":"17","author":"R Hast","year":"2003","unstructured":"Hast R, Hellstrom-Lindberg E, Ohm L, Bjorkholm M, Celsing F, Dahl IM et al (2003) No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leuk Off J Leuk Soc Am Leuk Res Fund UK 17(9):1827\u20131833","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"issue":"12","key":"2486_CR6","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/sj.leu.2403963","volume":"19","author":"U Germing","year":"2005","unstructured":"Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C et al (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leuk Off J Leuk Soc Am Leuk Res Fund UK 19(12):2223\u20132231","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"issue":"8","key":"2486_CR7","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","volume":"90","author":"E Estey","year":"1997","unstructured":"Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90(8):2969\u20132977","journal-title":"Blood"},{"issue":"5","key":"2486_CR8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/1097-0142(19900901)66:5<831::AID-CNCR2820660503>3.0.CO;2-E","volume":"66","author":"T Witte de","year":"1990","unstructured":"de Witte T, Muus P, De PB, Haanen C (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66(5):831\u2013837","journal-title":"Cancer"},{"issue":"11","key":"2486_CR9","first-page":"1805","volume":"9","author":"T Witte de","year":"1995","unstructured":"de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M et al (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leuk Off J Leuk Soc Am Leuk Res Fund UK 9(11):1805\u20131811","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"issue":"4","key":"2486_CR10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","volume":"99","author":"JE Parker","year":"1997","unstructured":"Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al (1997) Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 99(4):939\u2013944","journal-title":"Br J Haematol"},{"issue":"4","key":"2486_CR11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.2009.22.9088","volume":"28","author":"AK Burnett","year":"2010","unstructured":"Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF et al (2010) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 28(4):586\u2013595","journal-title":"J Clin Oncol"},{"issue":"8","key":"2486_CR12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00277-004-0889-0","volume":"83","author":"WK Hofmann","year":"2004","unstructured":"Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L et al (2004) Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 83(8):498\u2013503","journal-title":"Ann Hematol"},{"issue":"6","key":"2486_CR13","first-page":"998","volume":"8","author":"P Lepelley","year":"1994","unstructured":"Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P (1994) Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leuk Off J Leuk Soc Am Leuk Res Fund UK 8(6):998\u20131004","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"issue":"1","key":"2486_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0145-2126(90)90141-U","volume":"14","author":"H Sato","year":"1990","unstructured":"Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg AA et al (1990) Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res 14(1):11\u201321","journal-title":"Leuk Res"},{"issue":"7","key":"2486_CR15","first-page":"963","volume":"7","author":"P Sonneveld","year":"1993","unstructured":"Sonneveld P, van Dongen JJ, Hagemeijer A, van Kapel L, Nooter K, Schoester M et al (1993) High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leuk Off J Leuk Soc Am Leuk Res Fund UK 7(7):963\u2013969","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"issue":"9","key":"2486_CR16","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","volume":"89","author":"CP Leith","year":"1997","unstructured":"Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89(9):3323\u20133329","journal-title":"Blood"},{"issue":"10","key":"2486_CR17","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3324\/haematol.2009.019182","volume":"95","author":"T Witte de","year":"2010","unstructured":"de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G et al (2010) Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 95(10):1754\u20131761","journal-title":"Haematologica"},{"issue":"14","key":"2486_CR18","first-page":"3336","volume":"53","author":"LM Hinman","year":"1993","unstructured":"Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53(14):3336\u20133342","journal-title":"Cancer Res"},{"issue":"2","key":"2486_CR19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","volume":"19","author":"ML Linenberger","year":"2005","unstructured":"Linenberger ML (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leuk Off J Leuk Soc Am Leuk Res Fund UK 19(2):176\u2013182","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"issue":"3","key":"2486_CR20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2141.2010.08095.x","volume":"149","author":"S Amadori","year":"2010","unstructured":"Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L et al (2010) Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol 149(3):376\u2013382","journal-title":"Br J Haematol"},{"issue":"8","key":"2486_CR21","first-page":"950","volume":"89","author":"S Amadori","year":"2004","unstructured":"Amadori S, Suciu S, Willemze R, Mandelli F, Selleslag D, Stauder R et al (2004) Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 89(8):950\u2013956","journal-title":"Haematologica"},{"issue":"35","key":"2486_CR22","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2013.49.0771","volume":"31","author":"S Amadori","year":"2013","unstructured":"Amadori S, Suciu S, Stasi R, Salih HR, Selleslag D, Muus P et al (2013) Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol Off J Am Soc Clin Oncol 31(35):4424\u20134430","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"2486_CR23","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol Off J Am Soc Clin Oncol 19(13):3244\u20133254","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"2486_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108(2):419\u2013425","journal-title":"Blood"},{"issue":"4","key":"2486_CR25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1046\/j.1365-2141.1998.00870.x","volume":"102","author":"E Wattel","year":"1998","unstructured":"Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A et al (1998) Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 102(4):1015\u20131024","journal-title":"Br J Haematol"},{"issue":"8","key":"2486_CR26","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2003-07-2195","volume":"103","author":"GJ Ossenkoppele","year":"2004","unstructured":"Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF et al (2004) The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 103(8):2908\u20132913","journal-title":"Blood"},{"issue":"9","key":"2486_CR27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15(9):986\u2013996","journal-title":"Lancet Oncol"},{"issue":"4","key":"2486_CR28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29(4):369\u2013377","journal-title":"J Clin Oncol"},{"issue":"32","key":"2486_CR29","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","volume":"30","author":"AK Burnett","year":"2012","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L et al (2012) Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 30(32):3924\u20133931","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"2486_CR30","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","volume":"98","author":"T Witte de","year":"2001","unstructured":"de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al (2001) Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98(8):2326\u20132331","journal-title":"Blood"},{"issue":"10","key":"2486_CR31","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","volume":"97","author":"VH Velden van Der","year":"2001","unstructured":"van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97(10):3197\u20133204","journal-title":"Blood"},{"issue":"9825","key":"2486_CR32","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379(9825):1508\u20131516","journal-title":"Lancet"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2486-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2486-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2486-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T20:57:18Z","timestamp":1599598638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2486-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,26]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2486"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2486-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,26]]}}}